Beneficient 8-K filings

Beneficient is at risk of being delisted from the Nasdaq due to a lack of independent directors on its audit committee following the resignation of two board members.

Beneficient has received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement and has until August 30, 2024, to submit a plan to regain compliance.

Beneficient announced its financial results for the fourth quarter and fiscal year ended March 31, 2024, highlighting new product launches, cost reductions, and an expanded GP Solutions program.

Beneficient announced the conclusion of an SEC investigation without planned enforcement action, leading to a delay in their annual report and earnings release.

Beneficient stockholders approved the issuance of shares to Yorkville and a proposal to adjourn the meeting if necessary.

Beneficient has received notice from Nasdaq that it has regained compliance with the minimum bid price requirement, allowing its securities to continue trading on the exchange.

Beneficient presented its strategy for providing liquidity solutions in the alternative asset market, targeting mid-to-high net worth individuals and small-to-medium sized institutions.

Beneficient reports the resignation of a key executive and a significant arbitration loss totaling $55.3 million, plus interest and arbitration costs.

Beneficient has announced a 1-for-80 reverse stock split of its Class A and Class B common stock, effective April 18, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Beneficient is facing potential delisting from the Nasdaq Capital Market due to its low stock price and is issuing new preferred stock to a consultant.

Beneficient's stockholders approved a reverse stock split proposal and a proposal to adjourn the meeting if necessary to secure sufficient votes for the reverse stock split.

Richard W. Fisher retired from Beneficient's Board of Directors effective March 15, 2024, and will transition to a consultant role.

Beneficient has agreed to a liquidity financing transaction with three ff Venture Capital funds, potentially increasing its loan portfolio collateral by up to $121.5 million.

Beneficient announced its financial results for the third quarter of fiscal year 2024, showcasing growth in its GP Solutions program and a significant reduction in operating expenses.

Beneficient has issued Series B-2 and B-3 convertible preferred stock in separate transactions, including a liquidity financing and a vendor agreement.